GB Sciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2021
February 11, 2022 at 05:18 pm EST
Share
GB Sciences, Inc. reported earnings results for the third quarter and nine months ended December 31, 2021. For the third quarter, the company reported net income was USD 4.33 million compared to net loss of USD 0.593984 million a year ago. Basic earnings per share from continuing operations was USD 0.01. Diluted earnings per share from continuing operations was USD 0.01. Basic earnings per share was USD 0.01. Diluted earnings per share was USD 0.01.
For the nine months, net income was USD 3.14 million compared to net loss of USD 3.25 million a year ago. Basic earnings per share from continuing operations was USD 0.01 compared to basic loss per share from continuing operations of USD 0.01 a year ago. Diluted earnings per share from continuing operations was USD 0.01 compared to diluted loss per share from continuing operations of USD 0.01 a year ago. Basic earnings per share was USD 0.01 compared to basic loss per share of USD 0.01 a year ago. Diluted earnings per share was USD 0.01 compared to diluted loss per share of USD 0.01 a year ago.
GB Sciences, Inc. is a biopharmaceutical research and development company. The Company develops disease-targeted formulations of cannabis and other plant-inspired therapeutic mixtures for the prescription drug market through its wholly owned subsidiary, GbS Global Biopharma, Inc. (GBSGB). The Company's primary focus is on preparing its lead program for the treatment of the motor symptoms of Parkinson's disease (PD) in a human clinical trial. Through GBSGB, the Company is engaged in the research and development of plant-inspired medicines, with virtual operations in North America and Europe. GBSGB has a portfolio of intellectual property containing both plant-inspired formulations and its artificial intelligence (AI)-enabled drug discovery platform, as well as research contracts and various supplier arrangements. GBSGBs intellectual property covers a range of over 65 medical conditions, from which five drug development programs are in the preclinical stage of drug development.
GB SCIENCES, INC. 
